BCX-25

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameBCX-25
Drug Alias NameBCX-25
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPurine nucleoside phosphorylase inhibitors
TargetsPurine nucleoside phosphorylase
Therapy Area/IndicationsDiabetes MellitusLupus Erythematosus, SystemicArthritis, Rheumatoid +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBiocryst Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiocryst Pharmaceuticals IncNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsDiabetes MellitusLupus Erythematosus, SystemicArthritis, Rheumatoid +[4] 

Other Information

ATC CodeN/A
Related LinksN/A